Articles tagged with Cyclodextrins
Researchers at The University of Osaka developed a molecular design strategy to reconcile the trade-off between polymer material's durability and degradability. They created a tough material whose enzymatic degradation can be switched on or off using light, allowing for precise programming of its lifetime.
Researchers at Doshisha University have developed a synthetic, nontoxic antidote for hydrogen sulfide poisoning. The new compound, met-hemoCD-I, converts toxic hydrogen sulfide into harmless sulfite and sulfate ions.
Researchers developed a novel cyclic molecule that selectively traps phosphate species through multi-point hydrogen bonding in harmony with water molecules. The findings provide guidelines to design new cyclic molecules for aqueous environments, significant for materials development.
Researchers from Osaka University have developed tough biodegradable plastics with movable cyclodextrin crosslinks, which improve both durability and degradation capabilities. The new polymers can be broken down by enzymes into useful precursor molecules, reducing waste generation.
Scientists have created mirror-image cyclodextrins in the laboratory, which could make it easier to formulate and deliver complex medications. These discoveries may also lead to improved treatment of cardiovascular diseases caused by atherosclerotic plaques.
Scientists at DGIST developed a triboelectric nanogenerator using cyclodextrin, a green material from starch, to convert mechanical energy into electricity. The device can be reused and is biocompatible, making it suitable for wearable applications.
Researchers at KAIST designed nanoparticles that significantly reduce cholesterol and macrophage foam cells in arteries, two key triggers of atherosclerotic plaque. The combination drug delivery therapy showed great potential for treating and preventing atherosclerosis with reduced side effects.
Researchers have developed Pillar[n]MaxQ molecules that bind neuromuscular blocking chemicals with high specificity and strength. These new molecular containers show promise for eliminating toxins and malodorous substances in water, outperforming existing macrocyclic agents.
A new breakthrough in sensor technology uses a one-molecule-thick coating to improve detection of diseases and detect doping in sports. The coating, based on beta-cyclodextrin, produces sensors around ten times more sensitive than existing ones, allowing for earlier diagnosis and detection at lower concentrations.
A clinical trial shows promise for treating Niemann-Pick type C by slowing disease progression with cyclodextrin. The study found significant improvements in gait, cognition, and speech, with half of patients experiencing no worsening or improvement in neurological severity score.
Researchers developed a novel approach to strengthen polymer gels by modifying the length of polymer threads per molecular beads, increasing fracture resistance and strain strength. The technique enables fabrication of polymer gels with desired mechanical properties.
Researchers found that cyclodextrin reduces atherosclerotic plaques by reprogramming macrophages and dissolving cholesterol crystals. The treatment prevents plaque formation and reduces existing plaques in mice and human carotid arteries, pointing to cholesterol crystals as a target for atherosclerosis treatment.
Researchers at the University of Bonn discovered that cyclodextrin promotes the breakdown of cholesterol deposits in arteries, reducing inflammation and plaque formation. The ring-shaped sugar increases natural mechanisms for cholesterol breakdown and reduces inflammatory response, offering a potential new treatment for atherosclerosis.
Researchers are developing treatments for Niemann-Pick disease type C using cyclodextrin and delta-tocopherol, which have shown promise in studies of patient skin cells and animal models. The goal is to reduce lipid accumulation and improve symptoms in patients with this devastating rare disease.
A clinical trial to evaluate cyclodextrin as a potential treatment for Niemann-Pick disease type C1 has begun at the NIH Clinical Center. The disease, caused by cholesterol accumulation in cells, leads to progressive impairment of motor and intellectual function.
University of Illinois scientists have discovered a method to reduce the bitterness of ginseng in energy drinks by over half using cyclodextrins. This innovation could improve the health benefits of these beverages and expand their market, particularly in the US energy drink industry.
Researchers aim to overcome technical hurdles in new gene sequencing technology that could make genetic medicine possible with rapid, accurate, and low-cost sequencing of single DNA molecules. The method uses Atomic Force Microscopy and cyclodextrin molecules to read the sequence of amino acid code in the human genome.